Pueraria Mirifica
Herb ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Pueraria mirifica is a Thai tuber used in supplements for menopausal vasomotor, vaginal, skin, and breast-related claims because it contains potent phytoestrogens including miroestrol and deoxymiroestrol. Small clinical studies suggest possible benefit for menopausal symptoms and lipid markers, but evidence quality and long-term safety are limited. Because it has estrogenic activity, it is not appropriate for pregnancy, hormone-sensitive cancers, unexplained vaginal bleeding, or unsupervised use with hormone therapy.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Pueraria Mirifica is a herb most often used for may reduce menopausal symptom scores in small trials, may support vaginal dryness or urogenital symptoms in selected postmenopausal users, may modestly improve lipid markers. NutriStack rates the overall evidence as emerging. A typical adult dose is 25-50 mg/day standardized root tablet in clinical menopause studies; commercial products vary widely and higher doses should be avoided without clinician guidance, commonly taken as standardized pueraria mirifica root extract with disclosed plant part, extract ratio, and phytoestrogen content. This profile indexes 3 sources.
- Breast tenderness
- Headache
- Nausea
- Pregnancy and breastfeeding
- Current or prior estrogen-sensitive cancer unless oncology clinician approves3
The bottom line
Evidence rating emerging. Most-documented uses: may reduce menopausal symptom scores in small trials, may support vaginal dryness or urogenital symptoms in selected postmenopausal users, may modestly improve lipid markers. 3 sources indexed (2008–2018), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Isoflavones and chromenes in Pueraria mirifica can bind estrogen receptors and produce weak selective estrogenic effects in estrogen-responsive tissues. Miroestrol, deoxymiroestrol, coumestrol, daidzein, genistein, and puerarin may influence vasomotor symptoms, vaginal epithelium, bone turnover, and lipid handling, but potency and composition vary widely between products. The same estrogenic mechanism drives safety concerns in hormone-sensitive conditions and with other hormone-active products.3,1
Dosing & protocol.
Take with meals for tolerability. Product standardization is a major limitation because phytoestrogen content can vary by plant source, age, and extraction method.2
What it actually costs.
Real-world pricing across three quality tiers. Assumes Standardized root extract capsule.
Products with disclosed plant identity and standardization cost more but are safer to interpret. Updated 2026-06-04.
Full safety detail.
Side effects
- Breast tenderness
- Headache
- Nausea
- Menstrual spotting or bleeding changes
- Bloating
- Possible worsening of estrogen-sensitive symptoms
Contraindications
- Pregnancy and breastfeeding
- Current or prior estrogen-sensitive cancer unless oncology clinician approves3
- Unexplained vaginal bleeding
- Use in children or adolescents
- Use with estrogen, anti-estrogen, or fertility treatment without clinician supervision3
- History of venous thromboembolism or high-risk thrombosis without medical review
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forwardManonai J et al. · Journal of Ethnopharmacology · 2018
Small clinical trials suggested possible menopausal symptom benefit but highlighted the need for better long-term safety and standardization.
Randomized controlled trials
2- 2Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptomsManonai J et al. · Archives of Gynecology and Obstetrics · 2011
Both 25 mg and 50 mg daily were associated with symptom score improvement over 6 months in postmenopausal women.
- 3Pueraria mirifica phytoestrogens improve dyslipidemia in postmenopausal women probably by activating estrogen receptor subtypesOkamura S et al. · Tohoku Journal of Experimental Medicine · 2008
A small trial reported lipid changes consistent with estrogenic activity.
Common questions.
Quick answers about Pueraria Mirifica, drawn from the data on this page.
What is Pueraria Mirifica?
Pueraria mirifica is a Thai tuber used in supplements for menopausal vasomotor, vaginal, skin, and breast-related claims because it contains potent phytoestrogens including miroestrol and deoxymiroestrol. Small clinical studies suggest possible benefit for menopausal symptoms and lipid markers, but evidence quality and long-term safety are limited. Because it has estrogenic activity, it is not appropriate for pregnancy, hormone-sensitive cancers, unexplained vaginal bleeding, or unsupervised use with hormone therapy.
What is Pueraria Mirifica used for?
Commonly cited benefits of Pueraria Mirifica include: May reduce menopausal symptom scores in small trials; May support vaginal dryness or urogenital symptoms in selected postmenopausal users; May modestly improve lipid markers; Provides phytoestrogen activity. NutriStack rates the overall evidence as emerging.
What is a typical dose of Pueraria Mirifica?
A typical adult dose of Pueraria Mirifica is 25-50 mg/day standardized root tablet in clinical menopause studies; commercial products vary widely and higher doses should be avoided without clinician guidance. The commonly recommended form is Standardized Pueraria mirifica root extract with disclosed plant part, extract ratio, and phytoestrogen content. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Pueraria Mirifica?
Reported side effects include breast tenderness, headache, nausea, menstrual spotting or bleeding changes, bloating, possible worsening of estrogen-sensitive symptoms. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Pueraria Mirifica?
NutriStack rates this as Emerging, meaning early RCT signal, mechanistic data, or limited human evidence. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Pueraria Mirifica in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.